Pfizer criticised over delay in admitting drug's problemsBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7472.935-a (Published 21 October 2004) Cite this as: BMJ 2004;329:935
- Jeanne Lenzer
- New York
Pfizer delayed announcing negative data about its painkiller valdecoxib (Bextra), Curt Furberg, a member of the US Food and Drug Administration's Data Safety and Risk Management Advisory Committee, told the BMJ this week. When the company eventually presented its data to the FDA, it also left out important details, Dr Furberg alleges.
Pfizer stood to gain by …
Log in using your username and password
Log in through your institution
Sign up for a free trial